Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981385 | 0.95 | CAPN1 (0.59) | CTSKCAPN1CAPN2CPB1CPB2 | |
| SCHEMBL21981425 | 0.92 | CAPN1 (0.58) | CTSKCAPN1CAPN2CPB1CPB2 | |
| SCHEMBL21981423 | 0.92 | CAPN1 (0.58) | CTSKCAPN1CAPN2CPB1CPB2 | |
| SCHEMBL18095595 | 0.92 | SYK (0.54) | CTSKCAPN1CAPN2CPB1CPB2 | |
| SCHEMBL20669109 | 0.89 | CTSK (0.58) | CTSKCAPN1CAPN2MEN1RECQL | |
| SCHEMBL21981287 | 0.89 | CTSK (0.58) | CTSKCAPN1CAPN2MEN1RECQL | |
| SCHEMBL17039826 | 0.89 | FOLH1 (0.60) | CPB1CPB2FOLH1MAPTSIRT5 | |
| SCHEMBL21219296 | 0.89 | REN (0.57) | CAPN1CAPN2CPB1CPB2FOLH1 | |
| SCHEMBL21219294 | 0.89 | REN (0.57) | CAPN1CAPN2CPB1CPB2FOLH1 | |
| SCHEMBL22834040 | 0.88 | MAPT (0.59) | CAPN1CAPN2CPB1CPB2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287106-A1 | Method for Producing Fluorescent Probe Library Using Solid-Phase Extraction and Method of Measuring Enzyme Activity Using Same | RIKEN (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4353731-A1 | METHOD FOR PRODUCING FLUORESCENT PROBE LIBRARY USING SOLID-PHASE EXTRACTION AND METHOD OF MEASURING ENZYME ACTIVITY USING SAME | The University of Tokyo (JP) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260135-A1 | METHOD FOR PRODUCING FLUORESCENT PROBE LIBRARY USING SOLID-PHASE EXTRACTION AND METHOD OF MEASURING ENZYME ACTIVITY USING SAME | 国立大学法人 東京大学 | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287106-A1 | Method for Producing Fluorescent Probe Library Using Solid-Phase Extraction and Method of Measuring Enzyme Activity Using Same | NOTUM, GUSB, RNGTT | CTSK 144/4885CAPN1 642/4885CAPN2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.